Aramoto H, Saito H, Shigematsu H, Muto T
First Department of Surgery, Faculty of Medicine, University of Tokyo.
Nihon Rinsho. 1993 Jan;51(1):93-8.
Anticoagulant therapy, correction of the hypercoagulable state underlying DIC (disseminated intravascular coagulation), can help the treatment of DIC. Synthetic protease inhibitors, which can block serine proteases, such as thrombin and plasmin, in the coagulative-fibrinolytic system, could prevent activation of coagulation factors and development of DIC, if administered properly. Clinically applicated protease inhibitors at present, such as gabexate mesilate (FOY), nafamostat mesilate (FUTHAN), urinastatin (MIRACLID), do not have the same spectrum of action, but the common characteristics are as follows. These inhibitors may be superior to heparin and do not require antithrombin III for their activities because of the competitive inhibitors to coagulative enzymes. The half time of these agents in human circulating blood is within several minutes and shorter than that of heparin.
抗凝治疗，纠正弥散性血管内凝血（DIC）潜在的高凝状态，有助于DIC的治疗。合成蛋白酶抑制剂可阻断凝血-纤溶系统中的丝氨酸蛋白酶，如凝血酶和纤溶酶，如果使用得当，可预防凝血因子的激活和DIC的发展。目前临床应用的蛋白酶抑制剂，如甲磺酸加贝酯（FOY）、甲磺酸萘莫司他（FUTHAN）、乌司他丁（MIRACLID），作用谱不尽相同，但共同特点如下。这些抑制剂可能优于肝素，由于它们是凝血酶的竞争性抑制剂，其活性不需要抗凝血酶III。这些药物在人体循环血液中的半衰期在几分钟内，比肝素短。
